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NeBACKGROUND Studies of patients presenting for catheter ablation suggest that premature ventricular contractions
(PVCs) are a modiﬁable risk factor for congestive heart failure (CHF). The relationship among PVC frequency, incident
CHF, and mortality in the general population remains unknown.
OBJECTIVES The goal of this studywas to determine whether PVC frequency ascertained using a 24-h Holter monitor is a
predictor of a decrease in the left ventricular ejection fraction (LVEF), incident CHF, and death in a population-based cohort.
METHODS We studied 1,139 Cardiovascular Health Study (CHS) participants who were randomly assigned to 24-h
ambulatory electrocardiography (Holter) monitoring and who had a normal LVEF and no history of CHF. PVC frequency
was quantiﬁed using Holter studies, and LVEF was measured from baseline and 5-year echocardiograms. Participants
were followed for incident CHF and death.
RESULTS Those in the upper quartile versus the lowest quartile of PVC frequency had a multivariable-adjusted, 3-fold
greater odds of a 5-year decrease in LVEF (odds ratio [OR]: 3.10; 95% conﬁdence interval [CI]: 1.42 to 6.77; p ¼ 0.005), a
48% increased risk of incident CHF (HR: 1.48; 95% CI: 1.08 to 2.04; p ¼ 0.02), and a 31% increased risk of death
(HR: 1.31; 95% CI: 1.06 to 1.63; p ¼ 0.01) during a median follow-up of >13 years. Similar statistically signiﬁcant results
were observed for PVCs analyzed as a continuous variable. The speciﬁcity for the 15-year risk of CHF exceeded 90%
when PVCs included at least 0.7% of ventricular beats. The population-level risk for incident CHF attributed to PVCs was
8.1% (95% CI: 1.2% to 14.9%).
CONCLUSIONS In a population-based sample, a higher frequency of PVCs was associated with a decrease in LVEF,
an increase in incident CHF, and increased mortality. Because of the capacity to prevent PVCs through medical or
ablation therapy, PVCs may represent a modiﬁable risk factor for CHF and death. (J Am Coll Cardiol 2015;66:101–9)
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AND ACRONYMS
2D = 2-dimensional
AF = atrial ﬁbrillation
BMI = body mass index
CAD = coronary artery disease
CHF = congestive heart failure
CI = conﬁdence interval
ECG = electrocardiography
HR = hazard ratio
IQR = interquartile range
LV = left ventricular
LVEF = left ventricular
ejection fraction
MI = myocardial infarction
NPV = negative predictive
value
OR = odds ratio
PPV = positive predictive value
PVC = premature ventricular
contraction
VT = ventricular tachycardia
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102T he effect of premature ventricularcontraction (PVC) frequency on leftventricular (LV) systolic function,
incident congestive heart failure (CHF), or
mortality in the general population remains
unknown. Because the diurnal distribution
of ectopic beats can vary, 24-h Holter moni-
toring is essential to accurately assess peri-
odic events that contribute to the true
burden of PVCs (1,2). Because of the perva-SEE PAGE 110siveness of PVCs in the general population
and the number of “idiopathic” CHF patients
who contribute to signiﬁcant health care
resource use (3,4), it is important to under-
stand the association between PVC fre-
quency and myocardial function in the
general population. Therefore, we sought to
investigate PVC frequency ascertained using
a 24-h Holter monitor as a predictor of a
decrease in the left ventricular ejection frac-
tion (LVEF), incident CHF, and death in a
population-based cohort study.METHODS
STUDY DESIGN. The Cardiovascular Health Study
(CHS) is a prospective, community-based cohort study
sponsored by the National Heart, Lung, and Blood
Institute. Details regarding eligibility, enrollment, and
follow-up have been previously published (5–7).
Brieﬂy, 5,201 subjects 65 years of age or older were
recruited between 1989 and 1990 from a random sam-
ple of Medicare beneﬁciaries by 4 academic centers
(Johns Hopkins University, Wake Forest University,
University of Pittsburgh, and University of California,
Davis). An additional 687 black patients were recruited
between 1992 and 1993. All participants underwent a
medical history, physical examination, laboratory
testing, and 12-lead electrocardiography (ECG) at
enrollment. Participants were then followed with
annual clinic visits and semi-annual telephone contact
for 10 years, with telephone contact continued every 6
months thereafter.l CHS investigators and institutions can be found at CHS-NHLBI
does not necessarily represent the ofﬁcial views of the National
Monitoring Board for a clinical trial of a device funded by Zoll (Li
Access Project funded by Medtronic. Dr. Marcus has received resea
rs have reported that they have no relationships relevant to the
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
received October 15, 2014; revised manuscript received April 29STUDY COHORT. Our analysis was restricted to the
subset of 1,429 subjects who were randomly assigned
to 24-h ambulatory ECG (Holter) monitoring during
their initial assessment and who were part of the
initial recruitment cohort (those recruited between
1989 and 1990). Patients without a normal LVEF, as
determined by the baseline echocardiogram, or with
prevalent CHF were excluded from the study cohort.
HOLTER ASSESSMENT. Holter data were analyzed at
the Washington University School of Medicine Heart
Rate Variability Laboratory using a MARS 8000 Holter
scanner (GE Medical Systems, Milwaukee, Wiscon-
sin), and all PVC, atrial ﬁbrillation (AF), and ventric-
ular tachycardia (VT) episodes were identiﬁed. The
results were then manually reviewed to ensure
accuracy. The percentage of PVCs was determined by
dividing the total number of ventricular ectopic beats
by the total number of beats recorded during Holter
monitoring.
ECHOCARDIOGRAPHIC EVALUATION. The echocar-
diographic assessment of participants in the CHS
were previously described (8). In brief, 2-dimensional
(2D) echocardiography, 2D targeted M-mode, and
Doppler imaging were performed on each participant
at baseline using Toshiba SSH-160A echocardio-
graphic machines (Toshiba Medical Systems, Tustin,
California), equipped with 2.5- and 3.75-MHz trans-
ducers. Imaging was performed at the highest mega-
hertz that provided adequate tissue penetration for
2D imaging. Images were recorded and stored on
Super-VHS videotape at the recruitment sites and
then transferred to the University of California,
Irvine, for central interpretation. LV function was
qualitatively assessed from the 2D imaging views,
where at least 80% of the myocardium was visual-
ized. Function was subjectively categorized as
normal, borderline, or abnormal, with 94% inter-
reader agreement and 98% intrareader agreement of
paired studies (9). LV end-diastolic diameter and LV
mass were derived from M-mode measurements,
using leading-edge-to-leading-edge methodologies
per American Society of Echocardiography standards
(10). LV mass was calculated using the Devereux
formula and indexed by dividing by the body surface.org. The content is solely the responsibility of the
Institutes of Health. Dr. Psaty has served on the Data
feCor); and is on the Steering Committee of the Yale
rch support from Gilead Sciences and Medtronic. All
contents of this paper to disclose.
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103area. A second echocardiogram was performed 5 years
after enrollment (8).
COVARIATE ASCERTAINMENT. Self-identiﬁed race
was categorized as white, black, Asian/Paciﬁc
Islander, and other. Self-identiﬁed sex was classiﬁed
as male or female. Hypertension was deﬁned as either
a reported history of physician-diagnosed hyperten-
sion combined with the use of antihypertensive
medications or a baseline study visit systolic
blood pressure $140 mm Hg or diastolic pressure
$90 mm Hg. Diabetes was deﬁned as a reported use of
an antihyperglycemic medication at baseline or a
fasting glucose level $126 mmol/l. CHF and myocar-
dial infarction (MI) were identiﬁed by participant self-
report and were conﬁrmed by medical record
veriﬁcation (7). Coronary artery disease (CAD) was
deﬁned as angina, previous MI, previous coronary
artery bypass graft surgery, or previous angioplasty.
Baseline beta-blocker use was ascertained using an
in-home medication inventory, and was deﬁned as a
current prescription ﬁlled by a pharmacist or phy-
sician, and taken by the patient in the previous
2 weeks (11).
EVENT ASCERTAINMENT. Medical records were ob-
tained for all hospitalizations after study enrollment.
Potential incident CHF and MI events, hospitalized
and outpatient, were investigated in detail on the basis
of initial identiﬁcation through International Classiﬁ-
cation of Diseases (ICD) diagnostic codes, or mention
of an endpoint on the hospital face sheet, discharge
summary, or outpatient procedure report. Adjudica-
tion of incident CHF and MI events was performed by
the CHS Cardiac Events Subcommittee (6). For each
incident CHF event, all medical records 2 weeks before
and 30 days after the event were reviewed for any
LVEF assessments. The CHF event was considered to
be associated with systolic dysfunction if the LVEF
assessment closest in time was either documented as
qualitatively below normal or if the quantiﬁed LVEF
was <45%. Death was ascertained by reviewing med-
ical records, death certiﬁcates, autopsy examinations,
coroner’s reports, obituaries, and a search of the Na-
tional Death Index (5).
STATISTICAL ANALYSIS. Continuous variables with
a normal distribution are presented as mean  SD and
were compared using Student t tests. Non-normally
distributed continuous variables are presented as
medians with interquartile ranges (IQRs) and were
compared using Kruskal-Wallis tests. The association
between categorical variables was determined using
chi-square tests.
Continuous echocardiographic variables were
analyzed using linear regression, both before andafter adjusting for confounders identiﬁed a priori.
A reduction in LVEF from baseline to 5 years post-
enrollment was dichotomized into the presence or
absence of any LVEF reduction (any change from
normal to borderline or reduced function). Both un-
adjusted and adjusted analyses were performed using
logistic regression.
Incident CHF and mortality outcomes were
analyzed using unadjusted and adjusted Cox pro-
portional hazard models. The baseline covariates
used in the adjusted analyses were age, sex, race,
body mass index (BMI), and a history of hypertension,
diabetes, CAD, beta-blocker use, Holter-based AF,
and number of Holter-based VT episodes. Because all
patients with VT also had PVCs, the number of VT
episodes was used to better capture the effect of VT
burden. A separate multivariable Cox proportional
hazards model adjusting for time-updated MI
was performed. We used log base 2 and cubic
spline transformations of the PVC count to meet
model linearity assumptions. Because the spline-
transformed PVC counts did not signiﬁcantly change
the log-likelihood, all analyses except for the percent
attributable risk assessment were performed using
the log transformations. Because of the observation
that the mean LV mass index was larger in partici-
pants with PVC percentages above (vs. below) the
median, an additional analysis adjusting for LV mass
index was performed. For mediation analyses, we
calculated the “proportion of effect explained” as the
percentage reduction in the adjusted regression co-
efﬁcient after additional adjustment for the candidate
mediator, with a 95% bias-corrected percentile boot-
strap conﬁdence interval (CI).
Cox proportional hazards models incorporating
log-transformed percentage of PVC counts were used
to estimate the 15-year risk of CHF. Three models
were examined: the ﬁrst using PVC percentage alone;
the second using baseline covariates as previously
described; and the third using both the baseline
covariates and PVC percentage. Predicted risks from
the ﬁrst model were plotted against the percentage of
the PVC count, and sensitivity, speciﬁcity, positive
predictive value (PPV), and negative predictive value
(NPV) were calculated for various percentage of PVC
thresholds. Discrimination of each of the 3 models
was assessed using the cross-validated C-index; bias-
corrected 95% bootstrap percentile CIs were used to
assess differences in the C-index among the 3 models.
The population attributable risk for incident CHF
was calculated for the following covariates using a
counterfactual approach (12): PVCs, BMI, hyperten-
sion, age, and CAD. Population attributable risk was
estimated by calculating the ratio of the total excess
TABLE 1 Baseline Ch
Age, yrs
Female
Race
White
Black
Asian/Paciﬁc Islande
Other
BMI, kg/m2
Hypertension
Coronary artery disease
Diabetes
LV diastolic diameter in
LV mass index*, g/m2
Values are n (interquartile
BMI ¼ body mass index;
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104risk associated with the exposure of interest to the
total observed risk. The percentage of PVCs were
modeled using cubic splines, with a reference level of
the lower quartile of percentage of PVCs within the
cohort. For CAD and hypertension, the reference
levels were the absence of the respective disease. The
reference BMI was 23 kg/m2 (based on the center
of normal), and the reference age was 70 years
(the mean of the cohort). CIs for population attribut-
able risk estimates were obtained using bootstrap
resampling with 500 repetitions.
Data were analyzed using Stata 12 (StataCorp,
College Station, Texas). A 2-tailed p < 0.05 was con-
sidered statistically signiﬁcant.
RESULTS
At baseline, 1,139 CHS participants had Holter moni-
toring, echocardiograms that demonstrated normal
LV systolic function, and no prevalent CHF. Over a
median 22.2-h duration (IQR: 21.7 h to 22.8 h) of
Holter monitoring, PVCs represented a median
0.011% of all heartbeats (IQR: 0.002% to 0.123%). The
maximum recorded PVC percentage was 17.7%. The
baseline characteristics of these participants stratiﬁed
relative to the median PVC burden are shown in
Table 1. Other Holter monitor ﬁndings included 3
participants (0.26%) with episodes of AF and 63 par-
ticipants (5.5%) with runs of nonsustained VT (range:
0 to 106 episodes). No episodes of sustained VT were
noted, and all participants with VT also had PVCs.
ECHOCARDIOGRAPHIC CHANGES. At total of 842
subjects (74%) underwent the year 5 follow-uparacteristics of Participants Stratiﬁed by Median Percent PVCs
Below or Equal
to the Median of
Percent PVCs
(n ¼ 587)
Above the
Median of
Percent PVCs
(n ¼ 552) p Value
70 (68–74) 71 (68–74) 0.25
374 (66) 283 (50) <0.001
548 (96) 535 (94) 0.24
20 (4) 31 (5)
r 1 (0.2) 0 (0)
1 (0.2) 3 (0.6)
26.6  4.3 26.6  3.9 0.85
298 (52) 316 (56) 0.27
80 (14) 103 (18) 0.06
75 (13) 89 (16) 0.21
dex*, cm/m2 2.77  0.3 2.82  0.3 0.07
80.0  19.6 84.7  23.6 0.02
range), n (%), or mean  SD. *Index measurements are divided by body surface area.
LV ¼ left ventricular; PVCs ¼ premature ventricular contractions.echocardiogram. Those who did not undergo the
year 5 echocardiogram exhibited several statistically
signiﬁcantly differences (Online Table 1).
Over 5 years, each doubling of the baseline
PVC percentage was associated with a statistically
signiﬁcantly greater odds of a decrease in the LVEF
in both the unadjusted and adjusted analyses
(Central Illustration). Similar statistically signiﬁcant
associations were observed when PVC percentages
were analyzed as quartiles (Table 2). There was also a
graded relationship in the baseline mean PVC count in
those who demonstrated no change in LVEF (0.002%
PVCs), a change from normal to borderline LVEF
(0.03% PVCs), and a change from normal to abnormal
LVEF (0.3% PVCs) (p < 0.001). There were no signiﬁ-
cant associations between log-transformed PVC per-
centages or PVC percentage quartiles with either the
5-year change in the diastolic diameter index or LV
mass index.
INCIDENT CONGESTIVE HEART FAILURE. Over a
median follow-up of 13.7 years (IQR: 8.0 to 18.2), 308
participants (27%) developed incident CHF. The
baseline characteristics of those who did and did not
develop incident CHF are shown in Online Table 2.
PVC percentage was associated with incident CHF
in both unadjusted and multivariable-adjusted ana-
lyses (Central Illustration). Adjustment for time-
updated incident MI did not substantively change
these results. Similarly, after adjustment for LV mass
index (restricted to the 778 participants with Holter
data and the measurement available from the base-
line echocardiographic data), no meaningful differ-
ences were observed. PVC percentage analyzed as
quartiles was also associated with incident CHF
(Table 2, Figure 1). Both Holter-identiﬁed AF and
VT were independently associated with incident
CHF before and after multivariate adjustment
(Online Table 3).
Sixty-nine (22%) of the incident CHF events were
associated with evidence of systolic dysfunction; 110
participants (36%) exhibited preserved systolic
function, and 129 (42%) had insufﬁcient medical re-
cords to assess concomitant systolic function. After
excluding participants without known systolic func-
tion at the time of their incident CHF event, the PVC
percentage was associated with incident heart failure
with systolic dysfunction in both the unadjusted
(hazard ratio [HR]: 1.10; 95% CI: 1.03 to 1.17; p ¼
0.003) and adjusted (HR: 1.08; 95% CI: 1.01 to 1.15;
p ¼ 0.02) analyses. In contrast, PVC percentage failed
to predict incident heart failure with preserved sys-
tolic function (unadjusted HR: 1.04; 95% CI: 0.99 to
1.10; p ¼ 0.118; adjusted HR: 1.01; 95% CI: 0.96 to
1.07; p ¼ 0.62).
TABLE 2 Association Between Quartile of Percent PVC Count, LVEF Reduction,
Incident CHF, and Mortality
Variable Unadjusted 95% CI p Value Adjusted* 95% CI p Value
LVEF reduction
Quartile 1 Reference Reference
Quartile 2 OR: 1.46 0.64–3.33 0.37 OR: 1.18 0.50–2.77 0.71
Quartile 3 OR: 1.86 0.85–4.10 0.12 OR: 1.48 0.64–3.39 0.41
Quartile 4 OR: 4.02 1.91–8.45 <0.001 OR: 3.10 1.42–6.77 0.005
Test of trend <0.001 0.004
Incident CHF
Quartile 1 Reference Reference
Quartile 2 HR: 1.04 0.74–1.45 0.83 HR: 0.89 0.63–1.25 0.50
Quartile 3 HR: 1.16 0.83–1.60 0.39 HR: 0.89 0.64–1.26 0.52
Quartile 4 HR: 1.77 1.30–2.41 <0.001 HR: 1.48 1.08–2.04 0.02
Test of trend <0.001 0.02
Mortality
Quartile 1 Reference Reference
Quartile 2 HR: 1.25 1.01–1.55 0.04 HR: 1.01 0.81–1.26 0.95
Quartile 3 HR: 1.38 1.12–1.71 0.003 HR: 1.12 0.90–1.40 0.29
Quartile 4 HR: 1.60 1.30–1.98 <0.001 HR: 1.31 1.06–1.63 0.01
Test of trend <0.001 0.007
Quartiles 1 to 4 represent PVC burdens of 0% to 0.002%, 0.002% to 0.011%, 0.011% to 0.123%, and 0.123%
to 17.7%, respectively. *Adjusted for age, sex, race, BMI, and history of hypertension, diabetes, coronary artery
disease, beta-blocker use, Holter-based atrial ﬁbrillation, and number of Holter-based ventricular tachycardia
episodes.
CHF ¼ congestive heart failure; CI ¼ conﬁdence interval; HR ¼ hazard ratio; LVEF ¼ left ventricular ejection
fraction; OR ¼ odds ratio; other abbreviations as in Table 1.
CENTRAL ILLUSTRATION Associations Between Baseline Percent PVCs and 5-Year Reduction in LVEF,
Incident CHF, and Mortality
Dukes, J.W. et al. J Am Coll Cardiol. 2015; 66(2):101–9.
Squares represent unadjusted (salmon) and adjusted (blue) odds ratios (ORs) for log base 2-transformed percent of premature ventricular
contractions (PVCs) as a predictor of any reduction in qualitative left ventricular ejection fraction (LVEF) between the baseline and 5-year
echocardiograms or hazard ratios (HRs) for incident congestive heart failure (CHF) and mortality. Multivariable models included adjustment for
age, sex, race, body mass index, and a history of hypertension, diabetes, coronary artery disease, beta-blocker use, Holter-based atrial
ﬁbrillation, and number of Holter-based ventricular tachycardia episodes. Error bars indicate 95% conﬁdence intervals (CIs). HRs express the
increase in risk per doubling of the percent of PVCs.
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105MORTALITY. Over a median follow-up of 15.2 years
(IQR: 9.6 to 18.4 years), a total of 729 deaths (64%)
were identiﬁed. Whether analyzed as a continuous
variable (Central Illustration) or as quartiles (Table 2,
Figure 1), a higher PVC percentage was associated
with increased mortality in both unadjusted and
multivariable adjusted analyses. To assess how much
incident CHF might explain the PVC–mortality asso-
ciation, a mediation analysis adjusting for incident
CHF attenuated the relationship between percentage
of PVCs and mortality by 26.8% (percentage of treat-
ment explained, 95% CI: 0.9% to 67.9%).
TEST CHARACTERISTICS. In the CHF prediction
model using PVC percentage alone, the 15-year risk
for CHF rose abruptly as the percentage of PVCs
increased between 0% and 0.5%, with tapering of the
risk curve for PVC percentages >10% (Figure 2). The
speciﬁcity for CHF prediction exceeded 90% when
PVCs included at least 0.7% of total ventricular beats.
The PPV for the 15-year risk of incident CHF was
>50% for PVC percentages between 1.24% and 3.55%.
Cross-validated C-indexes were 0.566 for the Cox
model using PVC percentage alone, 0.587 for the
model using baseline covariates alone, and 0.594 for
the model using both. The 95% bootstrap CI for the
FIGURE 1 Rates of CHF and All-Cause Mortality by PVC Quartiles
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FIGURE 2 Test Characteristics of PVCs for 15-Year CHF Risk
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participant are listed for various unadjusted PVC cutoff values. Abbreviations as in Figure 1.
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106increase in the C-index achieved by adding PVCs to
the model using covariates only included 0 (95%
CI: –0.37 to 0.50).
POPULATION ATTRIBUTABLE RISK. The risk of
incident CHF that could be attributed to PVCs was
8.1% (95% CI: 1.2% to 14.9%) compared with a refer-
ence population with a percentage of PVCs equal to
the lower quartile of the cohort (Figure 3). This was of
a similar magnitude to the risk of CHF that could be
attributed to BMI, hypertension, age, and CAD.
DISCUSSION
In a population-based cohort of >1,100 participants
older than age 65 years, a higher frequency of PVCs
was associated with a decrease in LVEF, incident
CHF, and increased mortality both before and after
multivariable adjustment. The increase in mortality
appeared to be partly explained by incident CHF.
The percentage of PVCs was highly speciﬁc for the
15-year risk of CHF and yielded a clinically meaning-
ful PPV. The percent attributable risk of PVCs for
incident CHF was comparable to other CHF risk fac-
tors, such as BMI, hypertension, age, and CAD. These
ﬁndings suggest that PVCs may exhibit an important
association with heart failure in the general popula-
tion, and that future research investigating the
potential beneﬁts of PVC modiﬁcation or eradication
in select individuals may be warranted.
CHF currently affects >5 million Americans, and its
prevalence is expected to increase by 25% within the
next 15 years (13). Up to 50% of CHF cases have no
FIGURE 3 Population Attributable Risk of PVCs for Incident CHF
PVC
BMI
Hypertension
Age
CAD
0% 5% 10% 15% 20% 25% 30% 35%
Each bar represents the population-attributable risk for the listed covariates, with error
bars denoting 95% CIs. BMI ¼ body mass index (weight in kilograms divided by the square
of the height in meters); CAD ¼ coronary artery disease; other abbreviations as in Figure 1.
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107known etiology (4). Among the established risk fac-
tors for CHF, such as obesity, diabetes, hypertension,
and CAD (14), few, if any, are readily reversible.
Recent studies arising from electrophysiology
laboratories have demonstrated that systolic dys-
function may improve and even normalize after suc-
cessful ablation of high-burden PVCs (generally >10%
PVCs) (15–19). These data suggest that PVCs could be a
signiﬁcant and modiﬁable risk factor for incident
CHF. However, because these observations are limited to
patients already diagnosed with heart failure, these
studies are unable to provide the denominator of in-
dividuals at risk; to do this, we require a population-
based study with long-term follow-up, as provided by
the CHS.
No previous population-based study has quantiﬁed
the relationship between PVC frequency and heart
failure. Using 24-h Holter monitoring (considered
the reference standard for PVC quantiﬁcation) (1),
echocardiography, and incident CHF and mortality
data, we provide the ﬁrst evidence that PVC per-
centage predicts new systolic dysfunction, as well as
clinically diagnosed CHF and overall mortality. These
data are also the ﬁrst to quantify those relationships.
These results are supported by data from other
population-based studies. The ARIC (Atherosclerosis
Risk in Communities) Study demonstrated that the
dichotomized presence (vs. absence) of PVCs ascer-
tained from a 2-min recording increased the risk for
incident CHF, although, unlike the present study,
24-h PVC frequency and change in systolic function
data were not available (20). Other studies have
demonstrated an association of mortality with PVCs,
either in combined endpoints or speciﬁc subgroups.
In the Framingham Heart Study, PVCs detected using
a 1-h recording were associated with increased
mortality only in men without CAD (21). The Copen-
hagen Holter Study found an association between
>30 PVCs/h and a combined endpoint of death or
acute MI (22). Among 456 participants in the Men
Born in 1914 Study, 24-h Holter monitor-detected
PVCs predicted death due speciﬁcally to ischemic
heart disease (23). Our positive ﬁndings regarding
overall mortality as a standalone endpoint may be
due to this being the largest study to utilize 24-h
Holter monitoring and with the longest follow-up.
Although the pathophysiology underlying the rela-
tionship between a greater frequency of PVCs and
mortality remains unknown, our mediation analysis
suggests that incident CHF may explain at least part
of that association.
Consistent with the serial echocardiographic ﬁnd-
ings on all participants, the CHF events associated
with increasing PVCs appeared to be primarily due tosystolic dysfunction. The mechanism(s) by which
frequent PVCs may lead to systolic dysfunction re-
mains unknown; however, the available evidence
favors adverse ventricular remodeling that occurs
due to repeated dyssynchrony (24,25) and impaired
calcium handling (26), rather than a tachycardia-
induced cardiomyopathy (27).
To characterize the potential clinical interpretation
of these ﬁndings, we constructed test characteristics
for varying PVC percentages using the 15-year risk of
CHF as the reference outcome. Sensitivity was low,
reﬂecting the fact that few patients who developed
CHF had high PVC burdens. However, the speciﬁcity
was quite high, >90% for PVCs that represented as
little as 0.7% of the total ventricular beats and rising
to >99% for PVC percentages $10%. The PPV was
more clinically relevant; among those with 3% PVCs,
more than one-half would go on to develop heart
failure. In light of both the high speciﬁcity and PPV,
patients with high PVC burdens might warrant special
attention. These data also revealed a heightened CHF
risk at a far lower PVC percentage than previously
recognized (17,19). However, cross-validated C-in-
dexes showed that the discrimination of all 3 of the
prediction models was poor to moderate, at best.
Furthermore, adding the PVC percentage to the pre-
diction model for CHF using clinically available vari-
ables did not achieve statistically signiﬁcant increases
in discrimination, although substantial increases of
up to 5% could not be excluded. Further research
might be indicated to investigate the prognostic
utility of adding PVC burden to other established CHF
prediction models.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: PVCs
are associated with a decline in left ventricular func-
tion, exacerbation of clinical HF, and increased mor-
tality. These relationships exist in patients with low
PVC burdens, and risks increase with greater PVC
frequency.
COMPETENCY IN PATIENT CARE: The risk of
developing HF attributable to PVCs is comparable to
that of other HF risk factors such as body mass index,
hypertension, age, and coronary artery disease. Pa-
tients with frequent PVCs should be monitored over
time for development of left ventricular dysfunction
and clinical HF.
TRANSLATIONAL OUTLOOK: Additional research
is needed to evaluate the potential beneﬁts of PVC
suppression to reduce the risk of progressive ven-
tricular dysfunction and incident heart failure.
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108The percentage of incident CHF that could be
attributed to increased PVCs was similar to that of
other well-established risk factors (13). Unlike age,
which is immutable, or BMI, hypertension, and CAD,
whichmay have strong inherited components andmay
be difﬁcult to modify, PVCs can be readily eradicated
with radiofrequency ablation. Therefore, it is inter-
esting to speculate whether prophylactic treatment for
PVCs, with either medicines or ablation, might reduce
the burden of heart failure in the population. Howev-
er, future study is required before entertaining this in
clinical practice. For example, it is possible that some
proportion of this population-based cohort simply
manifested PVCs as the ﬁrst evidence (or as an
epiphenomenon) of a cardiomyopathy destined to
result in CHF. Because some patients with frequent
PVCs may never develop CHF, future studies would
need to more fully elucidate other covariates that
might identify ideal candidates for treatment and
would need to determine the relative risks and bene-
ﬁts of any prophylactic therapies to be considered.
STUDY LIMITATIONS. Our participants were pre-
dominately elderly and white, which might constrain
the generalizability of our results. We did not have
data on particular PVC coupling intervals, PVC QRS
durations, or PVC morphologies. We also did not
examine baseline or interim differences in medication
use, which might have biased our results in either
direction. Finally, despite data from the electrophys-
iology laboratory that PVCs caused heart failure in
some patients, and although we were conﬁdent of the
association between antecedent PVCs and the devel-
opment of CHF in our cohort, our observational study
did not prove a causal relationship.
CONCLUSIONS
An increased percentage of PVCs detected by 24-h
Holter monitoring was associated with a subsequent
decrease in the LVEF, increased incident CHF, and
increased mortality. These effects were observed at
a far lower PVC percentage than previously recog-
nized. The relationship between increased PVCs andmortality appeared to be at least partly mediated by
incident CHF. The speciﬁcity of PVCs for the long-
term diagnosis of CHF was high, and the risk of inci-
dent CHF attributable to PVCs was comparable to that
of other CHF risk factors. These ﬁndings suggest that
PVC might be an important cause of occult or “idio-
pathic” cardiomyopathy and might be an important
determinant of incident CHF among those with other
established CHF risk factors. Because of these observations
and the high prevalence of PVCs in the general popula-
tion, further research into the potential beneﬁts of PVC
suppression are warranted.
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